BRPI0510382A - complexo de inclusão e preparação farmacêutica - Google Patents

complexo de inclusão e preparação farmacêutica

Info

Publication number
BRPI0510382A
BRPI0510382A BRPI0510382-7A BRPI0510382A BRPI0510382A BR PI0510382 A BRPI0510382 A BR PI0510382A BR PI0510382 A BRPI0510382 A BR PI0510382A BR PI0510382 A BRPI0510382 A BR PI0510382A
Authority
BR
Brazil
Prior art keywords
inclusion complex
inclusion
benzimidazole derivative
pharmaceutical preparation
preparation
Prior art date
Application number
BRPI0510382-7A
Other languages
English (en)
Inventor
Nam Ho Kim
Jin Young Choi
Jae Sun Kim
Nam Kyu Lee
Je Ho Ryu
Yong Youn Hwang
Yong Ho Oh
Dong Sun Min
Key An Um
Wie-Jong Kwak
Do Seung Kum
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of BRPI0510382A publication Critical patent/BRPI0510382A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

COMPLEXO DE INCLUSãO E PREPARAçãO FARMACêUTICA. A presente invenção se refere a um complexo de inclusão contendo um derivado de benzimidazol com excelente estabilidade à armazenagem e um método para sua preparação. Em particular, a presente invenção se refere a um complexo de inclusão contendo um derivado de benzimidazol com aperfeiçoada estabilidade à armazenagem e a um método para sua preparação, em que um complexo de inclusão é fabricado conduzindo uma reação de inclusão combinando um derivado de benzimidazol, ciclodextrina e um polímero solúvel em água em uma solução alcalina aquosa a fim de ser formulado após estabilizar um derivado de benzimidazol instável a ácido.
BRPI0510382-7A 2004-04-30 2005-04-27 complexo de inclusão e preparação farmacêutica BRPI0510382A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040030583A KR20050105565A (ko) 2004-04-30 2004-04-30 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
PCT/KR2005/001214 WO2005110488A1 (en) 2004-04-30 2005-04-27 Stable pharmaceutical composition containing benzimidazole derivatives and method of manufacturing the same

Publications (1)

Publication Number Publication Date
BRPI0510382A true BRPI0510382A (pt) 2007-12-26

Family

ID=35394000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510382-7A BRPI0510382A (pt) 2004-04-30 2005-04-27 complexo de inclusão e preparação farmacêutica

Country Status (11)

Country Link
US (1) US20070212408A1 (pt)
EP (1) EP1742667A1 (pt)
JP (1) JP2007535533A (pt)
KR (1) KR20050105565A (pt)
CN (1) CN101010104A (pt)
AU (1) AU2005243793A1 (pt)
BR (1) BRPI0510382A (pt)
CA (1) CA2565168A1 (pt)
MX (1) MXPA06012569A (pt)
RU (1) RU2006142319A (pt)
WO (1) WO2005110488A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
AU2007322477A1 (en) * 2006-11-22 2008-05-29 Sk Chemicals Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
CN114195733B (zh) * 2022-01-07 2024-10-01 华东理工大学 一种抑制烯丙苯噻唑异构化的方法
CN116869840A (zh) * 2023-08-11 2023-10-13 广东万翔宝诚实业有限公司 一种改善皮肤的组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224049B (pt) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
KR960003605B1 (ko) * 1992-09-24 1996-03-20 영진약품공업주식회사 경구용 오메프라졸 약제의 코어 조성물을 제조하는 방법
CZ291842B6 (cs) * 1997-03-13 2003-06-18 Hexal Ag Farmaceutická formulace
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2005243793A1 (en) 2005-11-24
RU2006142319A (ru) 2008-06-10
KR20050105565A (ko) 2005-11-04
CA2565168A1 (en) 2005-11-24
EP1742667A1 (en) 2007-01-17
MXPA06012569A (es) 2007-01-26
CN101010104A (zh) 2007-08-01
US20070212408A1 (en) 2007-09-13
JP2007535533A (ja) 2007-12-06
WO2005110488A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
UY32761A (es) Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones
ECSP13012382A (es) Composiciones sólidas
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
MX2010005346A (es) Composiciones farmaceuticas.
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
CL2011002194A1 (es) Formulacion que comprende anticuerpo en un regulador de histidina-arginina ph 4.5 a 6.5; articulo de manufactura que comprende dicha formulacion; metodo para estabilizar un anticuerpo en una formulacion farmaceutica acuosa.
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
MX2012001359A (es) Articulos para el cuidado oral.
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
CO6290686A2 (es) Dabigatrán para la cateterización cardiaca intervencionista percutánea
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
GB201105050D0 (en) Pharmaceutical agent
MX340436B (es) Formulacion farmaceutica estable con descoloramiento limitado.
NI201200074A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina.
BR112014031934A2 (pt) método com base em euglobulina para determinar a atividade biológica de defibrotide
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
WO2009062874A3 (en) Benzimidazole derivatives and their use as fxr agonists
CY1111914T1 (el) Μεθοδος συνθεσης της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
BR112014002372A2 (pt) recuperação de petróleo
EA201071098A1 (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/69 (2017.01), A61P 1/